Aureus Asset Management LLC Takes $1.22 Million Position in United Therapeutics Corporation $UTHR

Aureus Asset Management LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,500 shares of the biotechnology company’s stock, valued at approximately $1,218,000.

Other large investors also recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $26,000. Activest Wealth Management boosted its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics in the fourth quarter valued at about $31,000. Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in United Therapeutics in the fourth quarter valued at about $48,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,540,358.40. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 636,168 shares of company stock worth $359,249,237 in the last quarter. 8.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Bank of America boosted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Trading Up 0.6%

Shares of UTHR stock opened at $551.47 on Thursday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm’s 50 day moving average is $565.95 and its 200-day moving average is $522.96. The firm has a market capitalization of $23.41 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the company posted $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.